Britain and America have forged a major bilateral deal that will maintain no import taxes on British pharmaceutical products being sold in the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these crucial products will stay at nothing for a timeframe of three years.
This deal comes after recent threats to hike import taxes on branded drug products, with figures floated as high as 100%.
"This arrangement between the United Kingdom bolsters the international landscape for new treatments and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement said.
Trade Importance
Medicines are one of the Britain's largest goods shipped to the US, which is clearly the primary market for major British pharmaceutical firms.
Statistics indicate that in the one-year period prior to the third quarter, the UK shipped medicines valued at billions to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This deal safeguards employment, stimulates investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement involves several notable changes from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must refund to the NHS to control costs will be capped at 15%. Previously, refunds topped 20%.
Recent Tensions
The pact comes amid a long-running tension between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that US consumers were charged significantly more for the identical medicines than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been pledged toward projects in the United States.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a proportion of its overall budget over the past decade.
